281 related articles for article (PubMed ID: 26480957)
1. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
Kobayashi Y; Kobayashi H; Giles JT; Hirano M; Nakajima Y; Takei M
Int J Rheum Dis; 2016 Nov; 19(11):1169-1174. PubMed ID: 26480957
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.
Kobayashi H; Kobayashi Y; Giles JT; Yoneyama K; Nakajima Y; Takei M
J Rheumatol; 2014 Oct; 41(10):1916-21. PubMed ID: 25128513
[TBL] [Abstract][Full Text] [Related]
3. Impact of biological treatment on left ventricular dysfunction determined by global circumferential, longitudinal and radial strain values using cardiac magnetic resonance imaging in patients with rheumatoid arthritis.
Yokoe I; Kobayashi H; Kobayashi Y; Nishiwaki A; Sugiyama K; Nagasawa Y; Ikumi N; Karasawa H; Okumura Y; Kitamura N; Takei M
Int J Rheum Dis; 2020 Oct; 23(10):1363-1371. PubMed ID: 32779338
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
8. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
[TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
Lazzerini PE; Acampa M; Capecchi PL; Fineschi I; Selvi E; Moscadelli V; Zimbone S; Gentile D; Galeazzi M; Laghi-Pasini F
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype.
Bissell LA; Erhayiem B; Hensor EMA; Fent G; Burska A; McDiarmid AK; Swoboda PP; Donica H; Plein S; Buch MH; Greenwood JP; Andrews J
Int J Cardiovasc Imaging; 2020 Mar; 36(3):491-501. PubMed ID: 32036488
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
Addimanda O; Possemato N; Macchioni P; Salvarani C
Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
[TBL] [Abstract][Full Text] [Related]
13. Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.
Kume K; Amano K; Yamada S; Hatta K; Kuwaba N; Ohta H
Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1477-81. PubMed ID: 21702090
[TBL] [Abstract][Full Text] [Related]
14. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
15. Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study.
Okano T; Inui K; Tada M; Sugioka Y; Mamoto K; Wakitani S; Koike T; Nakamura H
Rheumatol Int; 2016 Mar; 36(3):349-57. PubMed ID: 26438386
[TBL] [Abstract][Full Text] [Related]
16. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
17. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.
Akiyama M; Kaneko Y; Yamaoka K; Kondo H; Takeuchi T
Rheumatol Int; 2016 Jun; 36(6):881-9. PubMed ID: 27072347
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
Ahmadzadeh A; Farahmand AN; Gachkar L
Int J Rheum Dis; 2017 Feb; 20(2):231-237. PubMed ID: 26385018
[TBL] [Abstract][Full Text] [Related]
19. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
Gossec L; Steinberg G; Rouanet S; Combe B
Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
